Vivos Therapeutics, INC 8-K filings

Vivos Therapeutics announced a 17% increase in revenue and a 27% reduction in operating loss for the third quarter of 2024, alongside key operational milestones.

Vivos Therapeutics, Inc. has announced a registered direct offering to sell 1,363,812 shares of its common stock at $3.15 per share, raising approximately $4.3 million.

Vivos Therapeutics has received FDA 510(k) clearance for its oral medical device to treat moderate to severe obstructive sleep apnea in children aged 6 to 17, marking a significant milestone in pediatric sleep disorder treatment.

Vivos Therapeutics has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Vivos Therapeutics has approved a new equity incentive plan and amended employment agreements for its CEO and CFO, pending stockholder approval.

Vivos Therapeutics announced a 19% increase in revenue and a 31% decrease in operating expenses for the second quarter of 2024, alongside a new strategic marketing alliance.

Vivos Therapeutics has been granted continued listing on Nasdaq, contingent on demonstrating compliance with the minimum stockholders' equity requirement by August 15, 2024.

Vivos Therapeutics is facing potential delisting from Nasdaq due to failing to meet minimum stockholders' equity requirements, despite a recent $7.5 million private placement.

Vivos Therapeutics has closed a $7.5 million private placement and formed a strategic alliance to market and distribute its sleep apnea treatments, marking a significant shift in its business model.

Vivos Therapeutics has received a delisting notice from Nasdaq due to falling below the minimum stockholders' equity requirement, despite previously demonstrating compliance.

Vivos Therapeutics announced its first quarter 2024 financial results, showcasing reduced operating expenses and progress in expanding product offerings and regulatory approvals, including Medicare reimbursement for its CARE oral devices.

Vivos Therapeutics believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following recent capital raises, but acknowledges the need for further funding to maintain compliance.

Vivos Therapeutics announced its fourth quarter and full year 2023 financial results, showcasing a significant reduction in operating expenses and progress in FDA clearances for its sleep apnea treatments.

Vivos Therapeutics has successfully raised approximately $4 million through the exercise of existing warrants and issued new warrants as part of an inducement agreement.